Table S2: Baseline characteristics of studies included in the meta-analysis of the clinical benefit of statin therapy stratified by KIF6 carrier status

Study	Genetic Sub-Study Sample Size	Number of CVD Events	Treatment Comparison	Primary Outcome	Median Follow-up (y)	[1]Difference in average LDL (mmol/L)
CARE	2,697	290	Statin vs. placebo	CHD death or MI	5.0	-0.98
WOSCOPS	1,227	465	Statin vs. placebo	CHD death or MI	4.8	-1.16
PROVE-IT TIMI22	1,815	410	More intense statin vs. less intense statin	Death, MI, arterial revascularization, or hospitalization for ACS	2.1	-0.85
PROSPER	5,752	694	Statin vs. placebo	CHD death, MI, coronary revascularization	3.3	-1.04
HPS	18,348	4,185	Statin vs. placebo	CHD death, MI, stroke, arterial revascularization	5.4	-1.00
JUPITER	4,599	381	Statin vs. placebo	CHD death, MI, stroke, arterial revascularization, hospitalization for unstable angina	2.0	-1.09
TNT	6,541	648	More intense statin vs. less intense statin	CHD death, MI, stroke, resuscitated cardiac arrest	5.0	-0.62
IDEAL	8,781	234	More intense statin vs. less intense statin	CHD death, MI, resuscitated cardiac arrest	4.8	-0.59
TOTAL	50,060	7,307				

[1]Difference in average LDL (mmol/L) between either treatment allocation arm. Study acronyms are defined in Table S1.

Abbreviations: CHD: Coronary heart disease; MI: myocardial infarction; ACS: acute coronary syndrome.